Graves' ophthalmopathy
thyroid eye disease , TED (Abkürzung)
orbitopathia thyrogenes latin

It is known by a variety of terms, the most common being Graves' ophthalmopathy.

People who smoke are more likely to develop Graves' ophthalmopathy.

Most mild problems caused by Graves' ophthalmopathy go away on their own in 1 to 4 months.

Graves' ophthalmopathy may also get better if you take antithyroid medicine.

In Graves' ophthalmopathy the tissues and muscles behind the eyes become swollen.

Most people who develop Graves' ophthalmopathy have one or more of the following symptoms:

Development of Graves' ophthalmopathy may be independent of thyroid function.

If you have Graves' ophthalmopathy, it may get worse temporarily after radioactive iodine therapy.

Smoking increases your chances of developing Graves' ophthalmopathy.

You develop symptoms of Graves' ophthalmopathy, such as bulging, reddened eyes .

Graves' ophthalmopathy, which causes bulging, reddened eyes , among other symptoms.

Graves' ophthalmopathy is a possible complication of hyperthyroidism.

See a picture of Graves' ophthalmopathy .

Graves' ophthalmopathy due to Graves' disease, usually causes bilateral proptosis.

It is found in Graves' ophthalmopathy.

To help reduce dryness and discomfort, your doctor will treat your symptoms of Graves' ophthalmopathy.

Graves' ophthalmopathy (protrusion of one or both eyes)

People with Graves' ophthalmopathy develop eye problems, including bulging, reddened eyes; sensitivity to light; and blurring or double vision.

What is Graves' ophthalmopathy?

TRAbs are also useful in the diagnosis of Graves' Ophthalmopathy.

However, these need to be distuingished from Graves' ophthalmopathy, which can only occur in patients who have Graves' disease.

You may also take antithyroid medicine if you have Graves' ophthalmopathy and are going to be treated with radioactive iodine therapy.

If you take antithyroid medicine before you have radioactive iodine treatment, it may prevent your Graves' ophthalmopathy from getting worse.

In the absence of Graves' ophthalmopathy, patients may demonstrate other ophthalmic symptoms and signs due to hyperthyroidism:

Graves' ophthalmopathy may occur before, with, or after the onset of overt thyroid disease and usually has a slow onset over many months.

This treatment may make thyroid eye disease worse for a while.

Thyroid eye disease affects between 25-50% of patients with Graves' disease.

Access of patients with thyroid eye disease to specialist centres and expertise varies widely.

Examples include sarcoidosis, thyroid eye disease, and orbital pseudotumor.

Another auto-immune disease, thyroid eye disease affects vision and causes proptosis or bulging eyes.

Some patients suffering from the related condition of thyroid eye disease leading to diplopia because this condition can be worsened by radiotherapy treatment.

Six months of selenium supplements had a beneficial effect on thyroid eye disease and were associated with improvement in the quality of life of participants.

Thyroid eye disease is an inflammatory condition, which affects the orbital contents including the extraocular muscles and orbital fat.

Contraindications to RAI are pregnancy (absolute), ophthalmopathy (relative; it can aggravate thyroid eye disease), solitary nodules.

Janis Hickey, director, founded British Thyroid Foundation in 1991 after being diagnosed with Graves' disease and thyroid eye disease.

Studies have shown that medicine permanently lowers thyroid levels in up to half of people who use it.1 The medicine may reduce your risk of getting thyroid eye disease.

Abduction limitations which mimic VIth nerve palsy may result secondary to surgery, to trauma or as a result of other conditions such as myasthenia gravis or thyroid eye disease.

A large European study performed by the European Group On Graves' Orbitopathy (EUGOGO) has recently shown that the trace element selenium had a significant effect in patients with mild, active thyroid eye disease.

Radiation therapy can also be used in non-malignant conditions, such as the treatment of trigeminal neuralgia, severe thyroid eye disease, pterygium, pigmented villonodular synovitis, and prevention of keloid scar growth, vascular restenosis, and heterotopic ossification.